Evidence map›Paper›PMID 39572410›Full record

ArticleAnnals of hematology2024

Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry.

S Mathur, G Christou, R Delage, M Elemary, N Finn, M Geddes, D S Houston, M M Keating, D Khalaf, B Leber and 18 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

S MathurDepartment of Internal Medicine, University of Manitoba, Winnipeg, Canada.
G ChristouDivision of Hematology, The Ottawa Hospital, Ottawa, Canada.
R DelageHematology, CHU De Québec-Université Laval, Quebec City, Canada.
M ElemaryHematology, Saskatchewan Cancer Agency, Saskatoon, Canada.
N FinnHematology, Dr. Georges-L-Dumont University Hospital Centre, Moncton, Canada.
M GeddesHematology, Tom Baker Cancer Centre, Calgary, Canada.
D S HoustonDepartment of Internal Medicine, University of Manitoba, Winnipeg, Canada.
M M KeatingDivision of Hematology, Dalhousie University, Halifax, Canada.
D KhalafHematology/Oncology, Juravinski Cancer Centre, Hamilton, Canada.
B LeberHematology/Oncology, Juravinski Cancer Centre, Hamilton, Canada.
H LeitchHematology, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
S A LotherDivisions of Critical Care and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
L MozessohnHematology/Oncology, Odette Cancer Center, Toronto, Canada.
T NevillHematology, Vancouver General Hospital, Vancouver, Canada.
A ParmentierHematology/Oncology, Odette Cancer Center, Toronto, Canada.
K PaulsonDepartment of Internal Medicine, University of Manitoba, Winnipeg, Canada.
E RimmerDepartment of Internal Medicine, University of Manitoba, Winnipeg, Canada.
M SabloffDivision of Hematology, The Ottawa Hospital, Ottawa, Canada.
A ShamyHematology, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada.
E St-HilaireHematology, Dr. Georges-L-Dumont University Hospital Centre, Moncton, Canada.
J StorringHematology, McGill University Health Centre, Montreal, Canada.
K YeeHematology, Princess Margaret Cancer Centre, Toronto, Canada.
L ZhangHematology/Oncology, Odette Cancer Center, Toronto, Canada.
N ZhuHematology, University of Alberta Hospital, Edmonton, Canada.
A E HayHematology, Queen's University, Kingston, Canada.
R ZarychanskiDepartment of Internal Medicine, University of Manitoba, Winnipeg, Canada.
R BucksteinHematology/Oncology, Odette Cancer Center, Toronto, Canada.
Brett L HoustonDepartment of Internal Medicine, University of Manitoba, Winnipeg, Canada. bhouston@cancercare.mb.ca.

Funding

University of Manitoba N/A
6 · The paper itself

Abstract

Infections are a significant cause of morbidity and mortality in myelodysplastic syndrome (MDS). Precise estimates of infection frequency and severity with modern therapies are uncertain. We conducted a retrospective analysis of a prospective cohort enrolled in a Canadian MDS registry and characterized the frequency and severity of infectious complications. Among 1,115 patients enrolled in the registry from 2006 to 2022, 349 (31%) experienced fever/infection, 207 (19%) were hospitalized due to fever/infection, and 95 (9%) died from fever/infection. Patients with severe neutropenia (absolute neutrophil count < 0.5 × 10

Indexed as

InfectionsMyelodysplastic SyndromesRegistriesAdultAgedAged, 80 and overCanadaFemaleFeverHospitalizationHumansMaleMiddle AgedNeutropeniaProspective StudiesRetrospective StudiesHypomethylating agentsInfectionMyelodysplastic syndromesNeutropenia

Identifiers

PMID39572410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.